Skip to main content

Table 5 Predictive ability of the scoring system to differentiate between non-advanced and advanced ALNM (pN2-N3) at each cutoff point in the training and validation cohorts

From: Development and validation of a pre- and intra-operative scoring system that distinguishes between non-advanced and advanced axillary lymph node metastasis in breast cancer with positive sentinel lymph nodes: a retrospective study

Total score cutoffa

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

AUC (95% CI)

P value

Training Cohort

      

≦ 2

100.0

41.3

23.1

100.0

0.71 (0.68–0.73)

< 0.0001

≦ 3

97.3

59.9

29.9

99.2

0.79 (0.76–0.82)

0.0869

≦ 4

85.3

79.1

41.8

96.8

0.82 (0.78–0.87)

Reference

≦ 5

60.0

92.3

57.7

92.9

0.76 (0.70–0.82)

0.0218

≦ 6

52.0

96.0

69.6

91.9

0.74 (0.68–0.80)

0.0044

≦ 7

22.7

99.3

85.0

87.9

0.61 (0.56–0.66)

< 0.0001

≦ 8

10.7

99.8

88.9

86.4

0.55 (0.52–0.59)

< 0.0001

Validation Cohort

      

≦ 2

100.0

35.8

23.1

100.0

0.68 (0.65–0.71)

< 0.0001

≦ 3

98.0

55.1

29.6

99.3

0.76 (0.71–0.80)

0.0366

≦ 4

87.8

74.8

40.2

96.9

0.81 (0.76–0.87)

Reference

≦ 5

65.3

89.0

53.3

93.0

0.76 (0.69–0.83)

0.1171

≦ 6

55.1

92.5

58.7

91.4

0.74 (0.67–0.81)

0.00375

≦ 7

22.5

97.2

61.1

86.7

0.60 (0.54–0.66)

< 0.0001

≦ 8

10.2

99.2

71.4

85.1

0.55 (0.50–0.59)

< 0.0001

  1. ALNM axillary lymph node metastasis, AUC area under the receiver operating characteristic curve, CI confidence interval, NPV negative predictive value, PPV positive predictive value
  2. aThe scoring system is summarized in Table 3